David J. Augeri

5.5k total citations
21 papers, 870 citations indexed

About

David J. Augeri is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, David J. Augeri has authored 21 papers receiving a total of 870 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in David J. Augeri's work include Cancer, Hypoxia, and Metabolism (3 papers), Trace Elements in Health (3 papers) and Synthesis and Catalytic Reactions (2 papers). David J. Augeri is often cited by papers focused on Cancer, Hypoxia, and Metabolism (3 papers), Trace Elements in Health (3 papers) and Synthesis and Catalytic Reactions (2 papers). David J. Augeri collaborates with scholars based in United States, Italy and Canada. David J. Augeri's co-authors include Philip J. Hajduk, Stephen W. Fesik, Jianguo Yang, J. Mack, Stephen F. Betz, Renaldo Mendoza, S. David Kimball, Andrew M. Petros, Jürgen Dinges and Stewart N. Loh and has published in prestigious journals such as Journal of the American Chemical Society, Blood and Oncogene.

In The Last Decade

David J. Augeri

20 papers receiving 844 citations

Peers

David J. Augeri
Armando G. Villaseñor United States
J.P. Guilloteau France
Jean M. Severin United States
Marc Adler United States
Butrus Atrash United Kingdom
Martin Vogtherr Germany
Robert E. Babine United States
Wilhelm Stark Switzerland
Kenneth M. Comess United States
Cristina Lewis United States
Armando G. Villaseñor United States
David J. Augeri
Citations per year, relative to David J. Augeri David J. Augeri (= 1×) peers Armando G. Villaseñor

Countries citing papers authored by David J. Augeri

Since Specialization
Citations

This map shows the geographic impact of David J. Augeri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Augeri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Augeri more than expected).

Fields of papers citing papers by David J. Augeri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Augeri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Augeri. The network helps show where David J. Augeri may publish in the future.

Co-authorship network of co-authors of David J. Augeri

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Augeri. A scholar is included among the top collaborators of David J. Augeri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Augeri. David J. Augeri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gilleran, John, Edward B. Miller, Ashley Hutchinson, et al.. (2024). Structure–Activity Relationship of a Pyrrole Based Series of PfPKG Inhibitors as Anti-Malarials. Journal of Medicinal Chemistry. 67(5). 3467–3503. 3 indexed citations
2.
Silva-Diz, Victoria da, Bin Cao, Eric Chiles, et al.. (2021). A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. Blood. 138(15). 1317–1330. 8 indexed citations
3.
Li, Xiaoping, Rajesh K. Harijan, Bin Cao, et al.. (2021). Synthesis and Structural Characterization of Ricin Inhibitors Targeting Ribosome Binding Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry. 64(20). 15334–15348. 8 indexed citations
4.
Cao, Bin, Jingjing Guo, Hanlin Tao, et al.. (2021). Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models. Oncogene. 40(12). 2285–2295. 7 indexed citations
5.
Gilleran, John, Xin Yu, Bing Na, et al.. (2021). Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53. Journal of Medicinal Chemistry. 64(4). 2024–2045. 24 indexed citations
6.
Mondal, Arindam, Mehul Vora, Elaine Langenfeld, et al.. (2019). Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein. Cell Communication and Signaling. 17(1). 150–150. 6 indexed citations
7.
Bartucci, Monica, Mohamed S. Hussein, Michele Patrizii, et al.. (2017). Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma. Targeted Oncology. 12(4). 449–462. 19 indexed citations
8.
Blanden, Adam R., Xin Yu, Aaron J. Wolfe, et al.. (2015). Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore. Molecular Pharmacology. 87(5). 825–831. 69 indexed citations
9.
Yu, Xin, Adam R. Blanden, Sumana Narayanan, et al.. (2014). Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget. 5(19). 8879–8892. 82 indexed citations
10.
Oravecz, Tamás, Wei-Chun Chang, Kanchan G. Jhaver, et al.. (2013). OP0195 Genetic and Pharmacologic Inhibition of MST1 Blocks Lymphocyte Function and Protects Against Inflammation and Autoimmunity. Annals of the Rheumatic Diseases. 72. A118–A118.
11.
Petros, Andrew M., Jürgen Dinges, David J. Augeri, et al.. (2005). Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x L from NMR and Parallel Synthesis. Journal of Medicinal Chemistry. 49(2). 656–663. 229 indexed citations
12.
Hajduk, Philip J., Suzanne B. Shuker, David G. Nettesheim, et al.. (2002). NMR-Based Modification of Matrix Metalloproteinase Inhibitors with Improved Bioavailability. Journal of Medicinal Chemistry. 45(26). 5628–5639. 49 indexed citations
13.
Hajduk, Philip J., David J. Augeri, J. Mack, et al.. (2000). NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups. Journal of the American Chemical Society. 122(33). 7898–7904. 166 indexed citations
14.
Augeri, David J., Douglas Kalvin, Daniel A. Dickman, et al.. (1999). Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase. Bioorganic & Medicinal Chemistry Letters. 9(8). 1069–1074. 28 indexed citations
15.
Hajduk, Philip J., Jürgen Dinges, Jeffrey M. Schkeryantz, et al.. (1999). Novel Inhibitors of Erm Methyltransferases from NMR and Parallel Synthesis. Journal of Medicinal Chemistry. 42(19). 3852–3859. 80 indexed citations
16.
Augeri, David J., Stephen J. O’Connor, Bruce G. Szczepankiewicz, et al.. (1998). Potent and Selective Non-Cysteine-Containing Inhibitors of Protein Farnesyltransferase. Journal of Medicinal Chemistry. 41(22). 4288–4300. 38 indexed citations
17.
Augeri, David J. & A. Richard Chamberlin. (1994). N-Aminoaziridinylhydrazones: Highly diastereoselective alkylation without chelation, and a syn-directing effect. Tetrahedron Letters. 35(31). 5599–5602. 3 indexed citations
18.
Bordner, Jon, et al.. (1992). Novel [3+2] and [3+3] 4-quinolone annulations by tandem Claisen-Cope amidoalkylation reaction. The Journal of Organic Chemistry. 57(25). 6991–6995. 27 indexed citations
19.
Augeri, David J., et al.. (1990). Synthesis and antibacterial activity of 2,3‐dehydroofloxacin. Journal of Heterocyclic Chemistry. 27(5). 1509–1511. 4 indexed citations
20.
Augeri, David J., et al.. (1988). A convenient synthesis of 3,6-disubstituted 3,6-diazabicyclo[3.2.2]nonanes and 3,6-diazabicyclo[3.2.1]octanes. The Journal of Organic Chemistry. 53(4). 896–899. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Armando G. Villaseñor Breakdown of academic impact, for papers by J.P. Guilloteau Breakdown of academic impact, for papers by Jean M. Severin Breakdown of academic impact, for papers by Marc Adler Breakdown of academic impact, for papers by Butrus Atrash Breakdown of academic impact, for papers by Martin Vogtherr Breakdown of academic impact, for papers by Robert E. Babine Breakdown of academic impact, for papers by Wilhelm Stark Breakdown of academic impact, for papers by Kenneth M. Comess Breakdown of academic impact, for papers by Cristina Lewis
Rankless by CCL
2026